Aminocaproic Acid Reduces the Risk of Secondary Hemorrhage in Patients With Traumatic Hyphema

Medical interventions for traumatic hyphema

“…At the time of discharge, Kutner 1987 observed VA of 20/40 or better in 14 of 21 (67%) participants in the oral aminocaproic acid group and in 10 of 13 (77%) participants in the placebo group. Similarly, Pieramici 2003 reported that 10 of 24 (42%) participants in the topical aminocaproic acid group and 13 of 27 (48%) participants in the placebo group had VAs of 20/40 or better seven days after study enrolment.…”

“…Most studies included all age groups, although some studies excluded very young children (e.g. less than four or seven years) (Farber 1991; Kutner 1987; Marcus 1988; Pieramici 2003; Vangsted 1983; Welsh 1983), and one study included children only (Kraft 1987). Of studies reporting demographic data, the mean age of participants ranged from 10 to 32 years, and the proportion of male participants ranged from 67% to 100%.…”

“…Eight studies investigated the use of aminocaproic acid compared with placebo in treating traumatic hyphema: six studies prescribed oral aminocaproic acid (Christianson 1979; Crouch 1976; Kraft 1987; Kutner 1987; McGetrick 1983; Teboul 1995), and two studies prescribed topical aminocaproic acid (Karkhaneh 2003; Pieramici 2003). The dosage of oral aminocaproic acid used in five studies was 100 mg/kg of body weight every four hours for five days (Crouch 1976; Kraft 1987; Kutner 1987; McGetrick 1983; Teboul 1995), and the remaining study used a loading dose of 75 mg/kg of body weight, then doses of 60 mg/kg of body weight every four hours, although the length of treatment was not reported (Christianson 1979).…”

“…The dosage of oral aminocaproic acid used in five studies was 100 mg/kg of body weight every four hours for five days (Crouch 1976; Kraft 1987; Kutner 1987; McGetrick 1983; Teboul 1995), and the remaining study used a loading dose of 75 mg/kg of body weight, then doses of 60 mg/kg of body weight every four hours, although the length of treatment was not reported (Christianson 1979). In total, the six studies included 331 participants (34 to 94 participants per study); 175 participants were randomized to receive oral aminocaproic acid, and 156 participants were randomized to receive placebo pills.…”

“…Eighteen of the 27 included studies reported no exclusions or losses to follow-up, and thus used ITT analyses. Of the nine studies that excluded participants from the analysis, four studies excluded only one or two participants due to an adverse effect of treatment (Crouch 1997; Kutner 1987; Palmer 1986), treatment failure (Palmer 1986), or loss of a patient’s medical record (McGetrick 1983). The remaining five studies did not conduct ITT analyses, although all reported the number of exclusions and losses to follow-up.…”